Smartfem is a South Australia-based medical technology company dedicated to advancing women's health. The company is committed to enhancing the quality of life for women through products and services that address critical areas such as regenerative medicine and pelvic floor disorders.
Its flagship product is the Victoria Graft System (VGS), a regenerative autologous graft system that is redefining pelvic organ prolapse repair with accelerated healing and biologically compatible support. SmartFem is conducting extensive clinical research, exploring the broader potential of VGS as an autologous solution for tissue repair and augmentation across a range of surgical applications, including fistula repair and nerve and tendon reconstruction.
Contact
Dr Fariba Behnia Willison
Khosrow Dahi
Objectives
- To position Smartfem as an emerging leader in regenerative, autologous solutions for pelvic floor disorders, particularly pelvic organ prolapse (POP), while advancing clinical evidence through prospective and multi-centre studies to support safety, efficacy, and adoption of the Victoria Graft System (VGS)
- Securing regulatory expansion into key international markets including FDA clearance in the US, scaling manufacturing, quality systems (QMS), and supply chain for commercial growth
- Strengthening strategic partnerships with clinicians, hospitals, and distributors globally
- Driving commercialisation through investor engagement and reimbursement pathways
- Expanding the R&D pipeline into broader applications of autologous regenerative technologies, and positioning Smartfem as a leading innovation-driven medtech company from South Australia on the global stage